Targets › TNFSF13
4 programs from 4 companies in 8 trials: 4 Phase 2, 2 Phase 3, 1 Phase 1, 1 Phase 4; Genitourinary, Immunology, Oncology; next expected readout Jan 2027.
Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes. (UniProt, O75888)
Open in Phaseline: the race on TNFSF13, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tongji Hospital | Telitacicept Freeze-dried powder Injection 80mg TACI-Fc fusion protein targeting BLyS and APRIL | TNFSF13B, TNFSF13 | Phase 4 | Lupus or SLE | Mar 2027 |
| Otsuka | Sibeprenlimab Tumor necrosis factor ligand superfamily member 13 inhibitor | TNFSF13 | Phase 3 | Immunoglobulin A Nephropathy; Sjogren Disease; IgA Nephropathy | Jan 2027 |
| Vera Therapeutics | Atacicept Tumor necrosis factor ligand superfamily member 13B inhibitor; Tumor necrosis factor ligand superfamily member 13 inhibitor | TNFSF13B, TNFSF13 | Phase 3 | IgA Nephropathy; IgA Nephropathy (IgAN); pMN | Sep 2027 |
| Xuzhou Medical University | APRIL-BAFF-Bicephali CAR-T cells Dual-targeted CAR-T cell therapy against APRIL and BAFF ligands | TNFSF13, TNFSF13B | Phase 1 | Multiple Myeloma | Jan 2027 |
IgA Nephropathy (2) Multiple Myeloma (1) IgA Nephropathy (IgAN) (1) pMN (1) Lupus or SLE (1) Immunoglobulin A Nephropathy (1) Sjogren Disease (1)
antibody (2), mixed (1)
Xuzhou Medical University (1) Vera Therapeutics (1) Tongji Hospital (1) Otsuka (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.